NovaBridge Biosciences (NBP) Gains from Sales and Divestitures (2020 - 2025)
NovaBridge Biosciences (NBP) reported Gains from Sales and Divestitures of $910939.0 for Q4 2025, up 5593.37% quarter-over-quarter from $16000.0 in Q3 2025.
NovaBridge Biosciences (NBP) Gains from Sales and Divestitures (2020 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has 6 years of Gains from Sales and Divestitures data on file, last reported at $910939.0 in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $910939.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $910939.0 (changed N/A YoY), and the FY2025 annual result was $910939.0, changed N/A from the prior year.
- Gains from Sales and Divestitures climbed to $910939.0 in Q4 2025 per NBP's latest filing, from $16000.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $910939.0 in Q4 2025 and troughed at $1000.0 in Q2 2024.
- A 5-year average of $155697.4 and a median of $48022.2 in 2023 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2023 and 2025: Gains from Sales and Divestitures retreated 20.96% in 2023, then soared 1500.0% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $119328.0 in 2021, then dropped by 15.14% to $101267.6 in 2022, then retreated by 20.96% to $80044.4 in 2023, then sank by 98.75% to $1000.0 in 2024, then surged by 90993.9% to $910939.0 in 2025.
- Business Quant data shows NBP's Gains from Sales and Divestitures at $910939.0 in Q4 2025, $16000.0 in Q3 2025, and $16000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 910,939.00 |
| Dec 31, 2025 | 910,939.00 |
| Sep 30, 2025 | 16,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Dec 31, 2023 | 80,044.42 |
| Dec 31, 2023 | 80,044.42 |
| Dec 31, 2022 | 101,267.56 |
| Dec 31, 2022 | 101,267.56 |
| Dec 31, 2021 | 119,328.01 |
| Dec 31, 2021 | 119,328.01 |
| Dec 31, 2020 | 85,284.89 |
| Dec 31, 2020 | 85,284.89 |